Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease

Margaret A. Fischl, Kenneth Stanley, Ann C. Collier, Jean Marie Arduino, Daniel S. Stein, Judith E. Feinberg, J. Davis Allan, Jonathan C. Goldsmith, William G. Powderly

Research output: Contribution to journalArticle

116 Scopus citations

Abstract

Objective: To compare the safety and efficacy of continuing zidovudine therapy with that of zalcitabine alone or zalcitabine and zidovudine used together. Design: A randomized, double-blind, controlled trial. Setting: AIDS Clinical Trials units and National Hemophilia Foundation sites. Patients: 1001 patients with symptomatic human immunodeficiency (HIV) disease and 300 or fewer CD4 cells/mm3 or asymptomatic HIV disease and 200 or fewer CD4 cells/mm3 who had tolerated zidovudine therapy for 6 months or more. Intervention: Patients were randomly assigned to receive zidovudine, 600 mg/d; zalcitabine, 2.25 mg/d; or zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d. Measurements: The primary end point was time to disease progression or death. Results: The median follow-up time was 17.7 months. The estimated 12- month event-free rates were 70%, 67%, and 73%, respectively, for the zidovudine, zalcitabine, and combination groups (P = 0.26). A trend analysis showed significantly lower progression rates for combination therapy compared with zidovudine therapy as the pretreatment CD4 cell count increased (P = 0.027). For patients with 150 or more CD4 cells/mm3, those receiving combination therapy were less likely to have disease progression or to die than were those receiving zidovudine (relative risk, 0.51; 95% CI, 0.28 to 0.93; P = 0.029). We observed no difference between the zalcitabine and zidovudine groups (relative risk, 0.74; CI, 0.40 to 1.36; P = 0.33). For patients with 50 to 150 CD4 cells/mm3 or fewer than 50 CD4 cells/mm3, we found no differences among the treatment groups (P = 0.69 and P = 0.57, respectively). Severe toxic effects occurred less frequently among patients with 150 or more CD4 cells/mm3. Conclusions: We found no overall benefits of zalcitabine used alone or with zidovudine. However, a trend analysis suggested a better outcome for combination therapy compared with zidovudine as the pretreatment CD4 cell count increased.

Original languageEnglish (US)
Pages (from-to)24-32
Number of pages9
JournalAnnals of internal medicine
Volume122
Issue number1
DOIs
StatePublished - Jan 1 1995

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease'. Together they form a unique fingerprint.

  • Cite this

    Fischl, M. A., Stanley, K., Collier, A. C., Arduino, J. M., Stein, D. S., Feinberg, J. E., Allan, J. D., Goldsmith, J. C., & Powderly, W. G. (1995). Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Annals of internal medicine, 122(1), 24-32. https://doi.org/10.7326/0003-4819-122-1-199501010-00004